Clinical Trials News

Latest clinical-trials news and updates for US-listed public companies.

📣 Get clinical-trials alerts and analysis

Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

First Breakthrough Therapy Designation in the U.S. for SystImmune and Bristol Myers Squibb's Izalontamab brengitecan (Iza-bren) based on data from the BL-B01D1-101 (CN), BL-B01D1-203 (CN), and BL-B...

What regulatory timelines and reimbursement considerations could influence the long‑term revenue outlook for this new therapy? What are the potential market share gains versus existing EGFR‑targeted therapies and other ADC competitors in the advanced NSCLC space? How will the Breakthrough Therapy Designation for Izalontamab brengitecan affect Bristol Myers Squibb's upcoming earnings and stock valuation?
Symbol: BMS
6 days ago
Read more prnewswire

Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA

ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the di...

How does lisaftoclax’s Bcl‑2 inhibition strategy compare to existing and pipeline competitors in the higher‑risk MDS market? How will the clearance for a global Phase III study impact Ascentage Pharma's cash burn and financing requirements? What is the expected timeline for GLORA-4 trial results and potential regulatory approval?
Symbol: AAPG
6 days ago
Read more globenewswire

Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

- Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial

Are there any red flags or uncertainties in the update (e.g., patient enrollment rates, trial delays) that could pose downside risk? What is the expected impact on the company's revenue forecast for 2025‑2026 given the projected clinical and IP milestones? How might the trial results, if positive or negative, shift analyst consensus and target price estimates?
Symbol: ALRT
8 days ago
Read more globenewswire

Regen BioPharma Discusses Potential Impact of HemaXellerate on Chemotherapy Treament Market

SAN DIEGO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) today provided further insight into its planned Phase 1 clinical trial of HemaXellerate, the company’s ...

What is the projected impact on Regen BioPharma’s earnings guidance once HemaXellerate progresses to later‑stage trials? Are there any intellectual property or patent considerations that could affect the therapy’s commercial exclusivity? What are the key clinical endpoints for the expanded oncology applications and the probability of meeting them?
Symbol: RGBP
9 days ago
Read more globenewswire

BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile

What is the anticipated competitive landscape if BGE-102 advances to Phase 2/3 for CNS diseases? How could the trial’s outcomes impact BIOA’s cash burn rate and need for future financing? Will the Phase 1 enrollment numbers and dosing strategy provide sufficient data to de‑risk later‑stage development?
Symbol: BIOA
9 days ago
Read more globenewswire

Caris Life Sciences Demonstrates Scientific Rigor with Clinical Validation of FDA-Approved MI Cancer SeekÂź

IRVING, Texas, Aug. 15, 2025 /PRNewswire/ -- Caris Life SciencesÂź (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has published a study...

What risks remain regarding the commercialization and scalability of MI Cancer SeekÂź despite the positive validation? How might this news affect the valuation multiples (e.g., P/E, EV/EBITDA) for Caris Life Sciences relative to the sector? Could the validation results trigger new clinical trial collaborations or expansions of the product pipeline?
Symbol: CAI
9 days ago
Read more prnewswire

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025

2H 2025 is shaping up to be a defining year for LIXTE (Nasdaq: LIXT) and its lead compound LB-100

Are there any macro or sector‑wide factors that could amplify or dampen the stock’s response to the 2H 2025 trial readout? What historical price reaction has LIXTE exhibited to prior clinical trial announcements? How could the upcoming data release affect LIXTE’s trading volume and liquidity on Nasdaq?
Symbol: LIXT
9 days ago
Read more globenewswire

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH Results support potential of efruxifermin (EFX) to reduce risk of...

Will the results prompt any changes in the company's capital allocation or cash burn forecasts? What is the anticipated pricing strategy for efruxifermin and how could it affect profit margins? How will the trial's safety profile influence investor sentiment compared to competitors?
Symbol: AKRO
9 days ago
Read more globenewswire

Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B (MPS IIIB)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (OTCQB: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurologic...

Could the integrated data lead to broader indications for TA‑ERT beyond Sanfilippo Syndrome Type B, and what would that mean for valuation? What competitive landscape exists for enzyme replacement therapies in MPS IIIB, and does this study give Spruce a clear differentiation advantage? How does this data affect Spruce's cash burn rate and need for future financing rounds or dilutive equity raises?
Symbol: SPRB
9 days ago
Read more businesswire